Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • ymc
    Senior Member
    • Mar 2010
    • 496

    #1

    Ion S5 550 Chip - a serious competitor to NextSeq?



    It was announced two weeks ago. It can generate 26Gbp (200bp x 130M reads) in 3.5 hours.

    Not sure about the chip and reagent cost but the previous S5 540 chip's per Gbp cost is only double that of NextSeq 2x150 mode. I suspect 550 with 62.5% more throughput should be more competitive.

    If you are doing amplicon that typical requires either 200bp single from Ion or 2x150bp PE from NextSeq, it will become an even better deal.

    I have been working with Illumina data all the time. I am thinking seriously of switching to Ion because of this. I am worried about Ion's read quality though. How does its data compare to data generated by NextSeq 500/550?
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    Do you know if people are buying Ion in your part of the world?

    Comment

    • ymc
      Senior Member
      • Mar 2010
      • 496

      #3
      Originally posted by GenoMax View Post
      Do you know if people are buying Ion in your part of the world?
      Not really. Just one or two machines in the universities as far as I know.

      Previously, Ion was not on my radar because there remains gaps in performance. Now the gap seems to be gone and it seems like I am going to do quite a bit of amplicon, so Ion seems to make more sense now.

      Comment

      • GenoMax
        Senior Member
        • Feb 2008
        • 7142

        #4
        I have not seen any new ion around where I am either. I assume you are thinking of getting the sequencing done from an external provider then?

        Comment

        Latest Articles

        Collapse

        • SEQadmin2
          Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
          by SEQadmin2



          CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

          Despite this, “CRISPR helped turn genome editing from a specialized technique into
          ...
          07-31-2026, 11:01 AM
        • SEQadmin2
          Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
          by SEQadmin2


          Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

          The systematic characterization of the human proteome has
          ...
          07-20-2026, 11:48 AM

        ad_right_rmr

        Collapse

        News

        Collapse

        Topics Statistics Last Post
        Started by SEQadmin2, 08-06-2026, 07:41 AM
        0 responses
        23 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 08-03-2026, 10:13 AM
        0 responses
        39 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-31-2026, 02:55 AM
        0 responses
        44 views
        0 reactions
        Last Post SEQadmin2  
        Started by SEQadmin2, 07-24-2026, 12:17 PM
        0 responses
        27 views
        0 reactions
        Last Post SEQadmin2  
        Working...